Infliximab in primary Sjögren's syndrome: One‐year followup

Serge D. Steinfeld, Paul Demols, Thierry Appelboom

DOI: 10.1002/art.10674
Published: 2002-12
Container: Arthritis & Rheumatism
Publisher: Wiley
Open access: unknown

Credibility signals

serious concern Score 29/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/art.10674,
  title = {Infliximab in primary Sjögren's syndrome: One‐year followup},
  author = {Serge D. Steinfeld and Paul Demols and Thierry Appelboom},
  year = {2002},
  journal = {Arthritis \&amp; Rheumatism},
  doi = {10.1002/art.10674},
  url = {https://doi.org/10.1002/art.10674}
}

RIS

TY  - JOUR
TI  - Infliximab in primary Sjögren's syndrome: One‐year followup
AU  - Serge D. Steinfeld
AU  - Paul Demols
AU  - Thierry Appelboom
PY  - 2002
JO  - Arthritis &amp; Rheumatism
DO  - 10.1002/art.10674
UR  - https://doi.org/10.1002/art.10674
ER  -

APA

Steinfeld, S. D., Demols, P., & Appelboom, T. (2002). Infliximab in primary Sjögren's syndrome: One‐year followup. Arthritis & Rheumatism. https://doi.org/10.1002/art.10674

Source records

crossref · retrieved 2026-09-24T18:35:16.392Z